We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Haleon Plc | HLN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -3.20 | -0.96% | 329.60 | 16:35:25 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 332.90 | 329.90 | 335.90 | 329.60 | 332.80 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 29/02/2024 | Final | GBP | 0.042 | 14/03/2024 | 15/03/2024 | 16/05/2024 |
| 02/08/2023 | Interim | GBP | 0.018 | 24/08/2023 | 25/08/2023 | 05/10/2023 |
| 02/03/2023 | Final | GBP | 0.024 | 16/03/2023 | 17/03/2023 | 27/04/2023 |
| Top Posts |
|---|
Posted at 19/3/2024 10:11 by alphorn Not forgetting that a takeover is made easier if a large holder agrees to sell in advance to an acquirer. HLN IMO will get acquired at some point. |
Posted at 19/3/2024 10:06 by simon8 Agree on the divi, not good, GSK still have a rump holding too to offload so more of the same to come from them. I had only kept these post the demerger on the hope that they would be taken over, but guessing that is unlikely or way out in the future once both Pfizer and GSK have done selling... until they are both clear I think the share price will languish in in the current trading range. |
Posted at 18/3/2024 11:49 by alphorn Pfizer to cut stake in HLN - see above. |
Posted at 29/2/2024 11:36 by anhar Final divi 4.2pxd 14 March, pd 16 May Total for year 6.0p Trailing yield at 330p 1.8% which is low but I'm retaining the shares, received from the GSK demerger, as an income investor. |
Posted at 17/1/2024 23:11 by pdosullivan Another very welcome placing by GSK, which has now sold down two thirds of the shares it originally held post IPO. Given the cash HLN is throwing off and reports that it might sell one of its brands for up to USD800m I wonder if the company might bid GSK for some or all of its remaining stock later this year. |
Posted at 15/12/2023 13:45 by anhar Trailing yield is actually 1.3%. This is based on last 12m divis total 4.2p (22 final of 2.4p plus 23 interim 1.8p) on the share price of 319p. The 23 forecast is for 5.5p making a forward yield of 1.7%.Still very low though. I hold HLN acquired via the GSK demerger and what may be supporting the price, if you think there is a reason other than the normal random walk of share prices, is bid hopes, as you suggest. Everyone thinks that, making it less likely! |
Posted at 04/10/2023 09:33 by alphorn Not a very active thread. HLN may be worth a look? |
Posted at 02/3/2023 11:45 by gbh2 I was out and reinvested by 8;30am, dividend meagre prospects obscure imo, good luck to those that remain.. |
Posted at 17/1/2023 11:04 by zho See "Prospective dividend yield (next 12 months): 2.2%" That was written when the price was around 280p, so yes, more than 6p. |
Posted at 20/9/2022 17:07 by nerdlinger no dividend declared yet, the first divi is planned for full year results, from the prospectus:(G) Dividend policy Following the Demerger, the Company will adopt a dividend policy, which will reflect the longterm earnings and cash flow potential of the Group, consistent with maintaining sufficient financial flexibility and meeting the Group’s capital allocation priorities. The initial dividend is expected to be at the lower end of a 30 to 50 per cent. pay-out ratio, subject to Board approval. The Company expects to pay a dividend to Haleon Shareholders in relation to the second half of 2022 in H1 2023, subject to Board approval and following approval of the Company’s FY 2022 results. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
